CEO Executive AssistantInvestor relations in the pharmaceutical and biotech sector operates at a level of complexity and consequence that few other industries match. Clinical trial results can move a company’s market capitalization by billions of dollars overnight. Regulatory decisions can make or break multi-year commercial strategies. Pipeline milestones are public commitments that investors track obsessively. And in a sector where news is often technical, scientific, and rapidly changing, the quality of investor communication directly affects investor confidence and capital access.
Pharma CEOs face intense investor relations demands: earnings calls, investor day presentations, analyst meetings, non-deal roadshows, and the constant stream of clinical and regulatory news that requires communication to the market. If the CEO tries to own all of this personally, the investor relations function never develops the organizational capability to handle the substantial operational layer of IR, and the CEO is consumed by communications work at the expense of leading the organization.
Effective IR delegation requires the CEO to own the highest-stakes investor communications while building a Head of IR and communications team that manages the substantial operational layer of investor engagement.
Why Pharma IR Delegation Is Particularly Complex
Several features of pharma investor relations make delegation more complicated than in other industries.
The scientific content of communications requires expertise. Investor communications about clinical trial design, efficacy endpoints, safety data, and regulatory strategy require both scientific accuracy and investor accessibility. Few IR professionals have both scientific depth and investor communication experience, which creates a talent challenge and often pulls the CEO toward direct communication ownership.
The regulatory dimension of IR is significant. SEC regulations, FDA communication rules, and stock exchange requirements all govern what the company can say, when it can say it, and how it must disclose material information. The legal and compliance layer of IR requires professional management.
And the speed of news in biotech and pharma means that communication decisions sometimes must be made quickly, without the CEO’s direct involvement in every instance. Building a communication infrastructure that can respond appropriately to unexpected clinical data, competitive news, or regulatory developments without creating a CEO bottleneck is essential.
What the CEO Must Own in Investor Relations and Communications
Earnings calls. Quarterly earnings calls are CEO-owned communications. The CEO presents results, discusses strategic progress, and takes analyst questions. The CFO and Head of IR support extensively, but the CEO is the primary voice. Delegating earnings calls to the CFO is appropriate in some situations but is not the standard in the pharmaceutical sector, where investors expect CEO leadership.
Major clinical readout communications. When pivotal clinical trial data is ready for release, the CEO should own the communication strategy and be the primary spokesperson. These events are among the most consequential communications a biotech or pharma CEO delivers. Clinical readouts that demonstrate efficacy and safety, or those that reveal unexpected results, both require the CEO’s personal communication. The Head of IR and communications team manages the logistics, preparation, and follow-up.
Investor day strategy. Annual or periodic investor days are strategic communications events where the CEO presents the company’s scientific and commercial vision to the investment community. The CEO should own the strategic content and narrative of investor day. The IR team manages all logistics, coordinates presenter preparation, and handles investor scheduling and follow-up.
Key investor relationship development. The company’s most significant institutional investors, particularly those with large positions or influential views on the sector, warrant CEO-level relationship investment. Periodic meetings with key portfolio managers and healthcare analysts from major institutions represent an appropriate use of CEO time.
What the Head of IR and Communications Team Should Own
The Head of Investor Relations and communications team is the right owner for the operational and managerial layer of investor engagement. This includes:
- Analyst outreach and relationship management for the broader analyst community
- Non-deal roadshow logistics and scheduling
- Investor conference presentation scheduling and preparation support
- Quarterly earnings materials development including scripts, Q&A preparation, and financial supplements
- Press release drafting and review for all communications requiring SEC filing
- IR website content management
- Investor targeting and shareholder analysis
- Investor feedback collection and synthesis for the CEO and CFO
- Corporate communications including media relations, employee communications, and stakeholder communications
- Crisis communications preparation and protocol management
The CEO’s relationship with the Head of IR should focus on strategic communication direction, review of major communication materials, and preparation for the CEO’s direct investor engagements.
For perspective on how IR connects to commercial launch communication, see pharma commercial launch delegation.
Delegating Analyst Outreach
Sell-side analyst coverage and buy-side investor outreach are essential activities for maintaining the investment community’s understanding of the company’s scientific progress and strategic direction. These activities are largely owned by the Head of IR, with CEO involvement limited to the highest-priority relationships.
A practical approach to analyst outreach delegation:
Head of IR owns: Scheduling and managing one-on-one meetings with analysts at investor conferences, responding to routine analyst information requests, hosting analyst facility visits in coordination with scientific and commercial leadership, and tracking analyst coverage, price targets, and estimate consensus.
CEO participates when: An analyst is initiating or significantly revising coverage, an analyst has a materially negative view that warrants executive engagement, or a major institutional investor requests a CEO meeting.
CEO delegates away: Routine conference calls with analysts, follow-up questions after earnings calls, and investor conference breakout meetings that do not require CEO-level engagement.
Empowering the IR Team on Non-Deal Roadshow Logistics
Non-deal roadshows are investor engagement trips that may involve dozens of one-on-one meetings over several days. The logistics of these roadshows, including investor scheduling, travel planning, meeting preparation, and follow-up, are entirely owned by the IR team.
The CEO’s role in a non-deal roadshow is to be present and prepared for the investor meetings. The CEO should receive a well-prepared meeting briefing for each investor session, including investor background, key positions, likely questions, and any outstanding topics from previous discussions. The IR team manages everything else.
Empowering the IR team on roadshow logistics requires:
Clear scheduling authority. The IR team should have the authority to schedule CEO investor meetings based on investor priority and availability, within the CEO’s committed time blocks for investor engagement. The CEO should not be approving individual meeting schedules.
Strong materials support. The IR team should develop investor meeting materials, including corporate presentation updates, key data summaries, and Q&A preparation documents. The CEO reviews and refines these materials but should not be developing them from scratch.
Post-meeting feedback systems. The IR team should collect investor feedback after meetings, synthesize key themes, and brief the CEO on investor sentiment. This intelligence is valuable for communication strategy without requiring the CEO to conduct follow-up themselves.
Building Communications Governance for a Complex, News-Driven Company
A pharma or biotech company generates a continuous stream of information that has potential investor communication implications: clinical data updates, regulatory interactions, partnership announcements, scientific publications, personnel changes, and financial results. Managing this information flow requires robust communications governance.
A disclosure committee, typically including the CEO, CFO, General Counsel, Head of IR, and Chief Scientific Officer, provides oversight of material disclosure decisions. This committee should meet regularly and be available on short notice when unexpected developments require disclosure decisions. The CEO should chair or be a regular participant in this committee.
Below the disclosure committee, the communications team should have clear protocols for managing different types of information, including who can speak to media, what information can be shared with investors between earnings periods, and how to respond when unexpected clinical or regulatory news requires rapid communication.
Research from Harvard Business Review on investor relations effectiveness finds that companies with structured IR functions and disciplined communication strategies achieve better long-term investor relations outcomes than those with ad hoc approaches. Building this structure is the CEO’s responsibility, even though maintaining it is the Head of IR’s job.
For more on how pharma CEO delegation connects to HR leadership during major communications events, see pharma HR delegation.
Common Delegation Failures in Pharma IR and Communications
CEO unavailability for high-priority investor engagement. Some CEOs over-delegate IR and become too unavailable to investors for key communications. When major institutional investors cannot get CEO time and the IR team is managing all relationship interactions, investor confidence can erode. The CEO must remain accessible for the highest-priority investor relationships.
IR team without scientific depth. A pharma IR team that cannot accurately explain the company’s pipeline, scientific rationale, and clinical program is not well-equipped to build investor confidence. The CEO should ensure the IR team has or has access to the scientific expertise needed to communicate the company’s story credibly.
Communication strategy set by IR alone. Investor communication strategy, including the narrative arc of the company’s story, how to characterize scientific setbacks, and when to provide pipeline updates, requires CEO engagement. The IR team cannot own communication strategy independently; they execute a strategy the CEO must help define.
Reactive crisis communication. Pharma companies that do not prepare for adverse clinical results, regulatory setbacks, or other negative developments find themselves making rushed communication decisions under pressure. The CEO should work with the IR and communications team to develop communication contingency plans for foreseeable adverse scenarios.
Conclusion
Pharma CEOs who effectively delegate investor relations and communications build IR teams with genuine operational capability while ensuring the CEO is present and prepared for the high-stakes investor communications that the market expects. The CEO owns earnings calls, major clinical readout communications, investor day strategy, and key investor relationships. The Head of IR and communications team owns the operational infrastructure, analyst outreach, roadshow logistics, and routine investor engagement.
The result is an IR function that can sustain investor confidence through the complexity of drug development, a CEO who is not consumed by IR operations, and a company that can communicate effectively even in the most demanding moments of its development cycle.
Related Reading
For further context, explore How Pharma CEOs Delegate HR and Organizational Development and How Automotive CEOs Delegate Fixed Operations Management.